Combination chemotherapy with bleomycin (NSC 125066), adriamycin (NSC 123127), CCNU (NSC 79037), vincristine (NSC 67574), and mechlorethamine (NSC 762) (BACON) in squamous cell lung cancer

experience with 50 patients

R. B. Livingston, Lawrence Einhorn, M. A. Burgess

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

Fifty patients with inoperable squamous cell carcinoma of the lung (38 with extensive disease and 12 with limited disease) were treated with BACON. Tumor regression greater than 50% was observed in 17 patients (45%) with extensive disease and in four patients (33%) with limited disease. Stabilization of disease for at least 8 weeks was seen in four patients with extensive and eight patients with limited disease and this factor had the same prognostic importance as response with regard to survival. In extensive disease, responding and stable patients had a median survival time (MST) of 26 weeks from the start of therapy, while the MST for nonresponders was 9 weeks. The MST in patients with limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for placebo alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks rather than every 4 weeks. Further studies are necessary to determine whether the results of this study can be reproduced in a comparative trial. If so, attention should be given to the treatment of less advanced squamous cell lung cancer with a similar regimen.

Original languageEnglish (US)
Title of host publicationCANCER CHEMOTHER.REP.
Pages361-367
Number of pages7
Volume6
Edition2
StatePublished - 1975
Externally publishedYes

Fingerprint

Lomustine
Mechlorethamine
Squamous Cell Neoplasms
Bleomycin
Vincristine
Combination Drug Therapy
Doxorubicin
Lung Neoplasms
Survival
Survival Analysis
Squamous Cell Carcinoma
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Combination chemotherapy with bleomycin (NSC 125066), adriamycin (NSC 123127), CCNU (NSC 79037), vincristine (NSC 67574), and mechlorethamine (NSC 762) (BACON) in squamous cell lung cancer : experience with 50 patients. / Livingston, R. B.; Einhorn, Lawrence; Burgess, M. A.

CANCER CHEMOTHER.REP.. Vol. 6 2. ed. 1975. p. 361-367.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{b664f93a56834e049bae7d65e2371563,
title = "Combination chemotherapy with bleomycin (NSC 125066), adriamycin (NSC 123127), CCNU (NSC 79037), vincristine (NSC 67574), and mechlorethamine (NSC 762) (BACON) in squamous cell lung cancer: experience with 50 patients",
abstract = "Fifty patients with inoperable squamous cell carcinoma of the lung (38 with extensive disease and 12 with limited disease) were treated with BACON. Tumor regression greater than 50{\%} was observed in 17 patients (45{\%}) with extensive disease and in four patients (33{\%}) with limited disease. Stabilization of disease for at least 8 weeks was seen in four patients with extensive and eight patients with limited disease and this factor had the same prognostic importance as response with regard to survival. In extensive disease, responding and stable patients had a median survival time (MST) of 26 weeks from the start of therapy, while the MST for nonresponders was 9 weeks. The MST in patients with limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for placebo alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks rather than every 4 weeks. Further studies are necessary to determine whether the results of this study can be reproduced in a comparative trial. If so, attention should be given to the treatment of less advanced squamous cell lung cancer with a similar regimen.",
author = "Livingston, {R. B.} and Lawrence Einhorn and Burgess, {M. A.}",
year = "1975",
language = "English (US)",
volume = "6",
pages = "361--367",
booktitle = "CANCER CHEMOTHER.REP.",
edition = "2",

}

TY - CHAP

T1 - Combination chemotherapy with bleomycin (NSC 125066), adriamycin (NSC 123127), CCNU (NSC 79037), vincristine (NSC 67574), and mechlorethamine (NSC 762) (BACON) in squamous cell lung cancer

T2 - experience with 50 patients

AU - Livingston, R. B.

AU - Einhorn, Lawrence

AU - Burgess, M. A.

PY - 1975

Y1 - 1975

N2 - Fifty patients with inoperable squamous cell carcinoma of the lung (38 with extensive disease and 12 with limited disease) were treated with BACON. Tumor regression greater than 50% was observed in 17 patients (45%) with extensive disease and in four patients (33%) with limited disease. Stabilization of disease for at least 8 weeks was seen in four patients with extensive and eight patients with limited disease and this factor had the same prognostic importance as response with regard to survival. In extensive disease, responding and stable patients had a median survival time (MST) of 26 weeks from the start of therapy, while the MST for nonresponders was 9 weeks. The MST in patients with limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for placebo alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks rather than every 4 weeks. Further studies are necessary to determine whether the results of this study can be reproduced in a comparative trial. If so, attention should be given to the treatment of less advanced squamous cell lung cancer with a similar regimen.

AB - Fifty patients with inoperable squamous cell carcinoma of the lung (38 with extensive disease and 12 with limited disease) were treated with BACON. Tumor regression greater than 50% was observed in 17 patients (45%) with extensive disease and in four patients (33%) with limited disease. Stabilization of disease for at least 8 weeks was seen in four patients with extensive and eight patients with limited disease and this factor had the same prognostic importance as response with regard to survival. In extensive disease, responding and stable patients had a median survival time (MST) of 26 weeks from the start of therapy, while the MST for nonresponders was 9 weeks. The MST in patients with limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for placebo alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks rather than every 4 weeks. Further studies are necessary to determine whether the results of this study can be reproduced in a comparative trial. If so, attention should be given to the treatment of less advanced squamous cell lung cancer with a similar regimen.

UR - http://www.scopus.com/inward/record.url?scp=0016766156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016766156&partnerID=8YFLogxK

M3 - Chapter

VL - 6

SP - 361

EP - 367

BT - CANCER CHEMOTHER.REP.

ER -